https://sbrihealthcare.co.uk/impact-case-studies/case-studies/revolution-zero<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-29T17:13:37.673Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Plastics"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce the number of single-use items used by the National Health Service.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5034", "tablingMemberConstituency" : {"_value" : "Cannock Chase"}
, "tablingMemberPrinted" : [{"_value" : "Josh Newbury"}
], "uin" : "11075"}
, {"_about" : "http://data.parliament.uk/resources/1736894", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1736894/answer", "answerText" : {"_value" : "The Department has made no such assessment. The National Institute for Health and Care Excellence (NICE) makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE is currently evaluating rozanolixizumab, zilucoplan, and efgartigimod within their licensed indications for the treatment of myasthenia gravis, and has not yet published final guidance.<\/p>
The Department has received correspondence letters from constituents via their Member of Parliament regarding myasthenia gravis and the treatment for this condition, but there have not been any recent meetings between Ministers and patients with this condition.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-29T16:51:04.317Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Myasthenia Gravis: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of making (a) rozanolixizumab, (b) zilucoplan and (c) efgartigimod available to NHS patients with myasthenia gravis (MG); and what (i) representations his Department has received from and (ii) meetings his Department has had with MG patients on that matter.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4813", "label" : {"_value" : "Biography information for Mr Richard Holden"}
}
, "tablingMemberConstituency" : {"_value" : "Basildon and Billericay"}
, "tablingMemberPrinted" : [{"_value" : "Mr Richard Holden"}
], "uin" : "11055"}
, {"_about" : "http://data.parliament.uk/resources/1736913", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1736913/answer", "answerText" : {"_value" : "
No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.<\/p>
The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.<\/p>
The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.<\/p>
The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.<\/p>
Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.<\/p>
Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
, "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "10995"}
, {"_value" : "10996"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736913/answer/previousversion/13733", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
}
, "questionFirstAnswered" : [{"_value" : "2024-10-30T16:30:29.643Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Chronic Fatigue Syndrome and Long Covid"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made with the Chancellor of the Exchequer of the potential impact of (a) ME and (b) long covid on economic growth.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4089", "label" : {"_value" : "Biography information for Tessa Munt"}
}
, "tablingMemberConstituency" : {"_value" : "Wells and Mendip Hills"}
, "tablingMemberPrinted" : [{"_value" : "Tessa Munt"}
], "uin" : "10994"}
, {"_about" : "http://data.parliament.uk/resources/1736914", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1736914/answer", "answerText" : {"_value" : "
No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.<\/p>
The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.<\/p>
The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.<\/p>
The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.<\/p>
Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.<\/p>
Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
, "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "10994"}
, {"_value" : "10996"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736914/answer/previousversion/13735", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
}
, "questionFirstAnswered" : [{"_value" : "2024-10-30T16:30:29.673Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Chronic Fatigue Syndrome and Long Covid"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the delivery plan for ME/CFS will include measures to improve the safety of NHS care for patients with ME.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4089", "label" : {"_value" : "Biography information for Tessa Munt"}
}
, "tablingMemberConstituency" : {"_value" : "Wells and Mendip Hills"}
, "tablingMemberPrinted" : [{"_value" : "Tessa Munt"}
], "uin" : "10995"}
, {"_about" : "http://data.parliament.uk/resources/1736915", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1736915/answer", "answerText" : {"_value" : "
No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.<\/p>
The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.<\/p>
The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.<\/p>
The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.<\/p>
Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.<\/p>
Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
, "dateOfAnswer" : {"_value" : "2024-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "10994"}
, {"_value" : "10995"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1736915/answer/previousversion/13734", "answeringMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
}
, "answeringMemberConstituency" : {"_value" : "Gorton and Denton"}
, "answeringMemberPrinted" : {"_value" : "Andrew Gwynne"}
}
, "questionFirstAnswered" : [{"_value" : "2024-10-30T16:30:29.72Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Chronic Fatigue Syndrome: Research"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of ring-fencing biomedical research funding for ME.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4089", "label" : {"_value" : "Biography information for Tessa Munt"}
}
, "tablingMemberConstituency" : {"_value" : "Wells and Mendip Hills"}
, "tablingMemberPrinted" : [{"_value" : "Tessa Munt"}
], "uin" : "10996"}
, {"_about" : "http://data.parliament.uk/resources/1736935", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1736935/answer", "answerText" : {"_value" : "
The Mental Health Bill announced in the King\u2019s Speech will deliver the Government\u2019s commitment to modernise the Mental Health Act 1983. The bill will be published when Parliamentary time allows.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4359", "label" : {"_value" : "Biography information for Stephen Kinnock"}
}
, "answeringMemberConstituency" : {"_value" : "Aberafan Maesteg"}
, "answeringMemberPrinted" : {"_value" : "Stephen Kinnock"}
, "dateOfAnswer" : {"_value" : "2024-10-31", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-31T11:39:36.923Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mental Health Act 1983"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, when his Department plans to bring forward legislative proposals to update the Mental Health Act 1983.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5142", "tablingMemberConstituency" : {"_value" : "Sheffield Central"}
, "tablingMemberPrinted" : [{"_value" : "Abtisam Mohamed"}
], "uin" : "11096"}
, {"_about" : "http://data.parliament.uk/resources/1736946", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1736946/answer", "answerText" : {"_value" : "
I refer the Hon. Member to the answer I gave on 9 September 2024 to Question 2902<\/a>.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-29T17:09:18.387Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prescriptions"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress his Department has made on the implementation of the recommendations of his Department's report entitled Good for you, good for us, good for everybody: A plan to reduce overprescribing to make patient care better and safer, support the NHS, and reduce carbon emissions, published on 22 September 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4267", "label" : {"_value" : "Biography information for Sarah Champion"}
}
, "tablingMemberConstituency" : {"_value" : "Rotherham"}
, "tablingMemberPrinted" : [{"_value" : "Sarah Champion"}
], "uin" : "11003"}
, {"_about" : "http://data.parliament.uk/resources/1736963", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1736963/answer", "answerText" : {"_value" : "Tackling waiting lists is a key part of our Health Mission. We will deliver an extra 40,000 operations, scans, and appointments, including dermatology appointments, each week, as a first step in our commitment to ensuring that patients can expect to be treated within 18 weeks.<\/p>
We will be supporting National Health Service trusts to deliver these through innovation, sharing best practice to increase productivity and efficiency, and ensuring the best value is delivered.<\/p>
The Government is committed to putting patients first. This means making sure that patients across all specialties, including dermatology, are seen on time, and ensuring that people have the best possible experience during their care.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-29T16:57:32.327Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Dermatology: Waiting Lists"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce dermatology waiting times.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5310", "tablingMemberConstituency" : {"_value" : "Newbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Lee Dillon"}
], "uin" : "11131"}
, {"_about" : "http://data.parliament.uk/resources/1736964", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1736964/answer", "answerText" : {"_value" : "
The Government is committed to putting patients first. This means making sure that patients are seen on time and ensuring that people have the best possible experience during their care, including for dermatology.<\/p>
Whilst no formal assessment has been made of the potential impact of waiting times from general practice (GP) referral to first appointment with a dermatology clinic on patients, dermatology services are being transformed to make sure that patients are seen on time. NHS England\u2019s Getting It Right First Time (GIRFT) programme is working with National Health Service trusts to deliver rapid clinical transformation, with the aim of reducing the numbers of patients waiting more than 52 weeks. The work brings together clinicians and operational teams to work collectively to transform patient pathways, reduce unnecessary appointments, and improve access and waiting times for patients.<\/p>
A clinical transformation group for dermatology was established in summer 2023, focusing on sharing and learning from best practice. Topics for collaboration have included innovative clinic models, for instance super clinics, best practice in the use of technology for telemedicine, best practice in reducing Did Not Attends, reducing unnecessary follow ups through Patient Initiated Follow Up, the role of artificial intelligence, how to develop nurses into advanced roles, and factors to help motivate and retain staff.<\/p>
GIRFT is also planning a programme to support primary care colleagues, offering training for new staff to recognise harmless skin lesions, like moles and warts, with the aim of reducing unnecessary referrals to hospital and freeing up capacity for other patients on the waiting list.<\/p>
Unpublished management information, as of 29 September 2024, from NHS England gives the average wait time for those waiting for first activity on a dermatology pathway of 15.4 weeks for the Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board, compared to 13.9 across the whole of England.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"}
}
, "answeringMemberConstituency" : {"_value" : "Bristol South"}
, "answeringMemberPrinted" : {"_value" : "Karin Smyth"}
, "dateOfAnswer" : {"_value" : "2024-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-10-29T17:17:04.537Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Dermatology: Waiting Lists"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of waiting times from GP referral to first appointment with dermatology clinic on patients; and what data his Department holds on average such waiting times (a) for NHS Buckinghamshire, Oxfordshire and Berkshire West ICB and (b) nationally.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : "http://data.parliament.uk/members/5310", "tablingMemberConstituency" : {"_value" : "Newbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Lee Dillon"}
], "uin" : "11132"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=1&min-dateTabled=2024-04-15&min-questionFirstAnswered.=2024-05-22T08%3A58%3A36.517Z", "page" : 0, "startIndex" : 1, "totalResults" : 2045, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}